PlerixaforThird Party Manufacturing in India

Plerixafor works by reversibly blocking the CXCR4 chemokine receptor, preventing its interaction with its natural ligand, stromal cell-derived factor-1 alpha (SDF-1α/CXCL12). Under normal conditions, the SDF-1α/CXCR4 complex anchors hematopoietic stem cells (HSCs) to the bone marrow microenvironment. By antagonizing CXCR4, plerixafor disrupts this attachment, triggering the rapid release and mobilization of stem cells from the bone marrow into the peripheral blood, where they can be collected for autologous transplantation.

Therapeutic Uses

Plerixafor is indicated for the mobilization of hematopoietic stem cells:

• Autologous Transplantation: Administered in combination with G-CSF to mobilize stem cells to the peripheral blood for collection in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).

Why Manufacturers Choose Plerixafor

Plerixafor is a niche, specialty critical-care injectable used in hematology and oncology transplant centers. Because of the sophisticated chemistry and clinical specialization involved, it has very low competitive density. This enables manufacturers and contract buyers to capture high-margin hospital business.

Sourcing Plerixafor third party manufacturing in India from WHO-GMP certified sterile plants guarantees international-grade purity and particle-free aseptic filling. With standard strengths like 20 mg/mL, Indian manufacturers offer reliable, premium-quality vials that meet strict regulatory requirements for export and domestic clinical use.